Targovax R&D Day: New York - October 11, 2018

New York, October 11, 2018

PLEASE JOIN US FOR A KOL EVENT

Leading experts discuss the oncolytic virus landscape and present interim data from Targovax’s ongoing melanoma and mesothelioma trials

 

 

General Agenda

11:30AM-12:00PM
Registration & Lunch

12:00-12:10PM
Welcome Remarks
Øystein Soug, CEO, Targovax

12:10-12:50PM
Oncolytic Virus Overview and Q&A
Dmitriy Zamarin, MD, PhD

12:50-1:30PM
Melanoma: the disease, CPIs, and lack of treatment options; Early ONCOS-102 data
Alexander N. Shoushtari, MD

1:30-1:50PM
Mesothelioma ORR Data
Magnus Jaderberg, CMO, Targovax

1:50-2:00PM
Closing Remarks
Øystein Soug, CEO, Targovax

RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Targovax [TRVX:OS] NKr490 MM MCap
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]

Location of the Event and Other Places